Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 31-Aug-16 6:21 PM View:  | Fekete Michael Director | Sagent Pharmaceuticals, Inc. (SGNT) | 29-Aug-16 | Disposition (change in control) | 2,041 | $21.75 | $44,391.80 | (100%) 2.04K to 0 | (< 1%) |
| 31-Aug-16 6:21 PM View: | Ward Michael V. Chief Legal Off. and Secretary | Sagent Pharmaceuticals, Inc. (SGNT) | 29-Aug-16 | Disposition (change in control) | 600 | $21.75 | $13,050.00 | (100%) 0.6K to 0 | (< 1%) |
| 31-Aug-16 6:24 PM View: | Bullock Donald R Executive V.P. Sales | Sagent Pharmaceuticals, Inc. (SGNT) | 29-Aug-16 | Disposition (change in control) | 2,583 | $21.75 | $56,180.20 | (100%) 2.58K to 0 | (< 1%) |
| 31-Aug-16 6:11 PM View: | Greve Jeffrey W. Vice President, Controller | Sagent Pharmaceuticals, Inc. (SGNT) | 29-Aug-16 | Disposition | 4,962 | $21.75 | $107,924.00 | (100%) 4.96K to 0 | (< 1%) |
| 31-Aug-16 6:21 PM View: | Ward Michael V. Chief Legal Off. and Secretary | Sagent Pharmaceuticals, Inc. (SGNT) | 29-Aug-16 | Disposition | 4,962 | $21.75 | $107,924.00 | (76%) 6.56K to 1.6K | (< 1%) |
| 31-Aug-16 6:23 PM View: | Flanagan Robert J Director | Sagent Pharmaceuticals, Inc. (SGNT) | 29-Aug-16 | Disposition (change in control) | 8,050 | $21.75 | $175,088.00 | (2%) 443.82K to 435.77K | (< 1%) |
| 31-Aug-16 6:21 PM View: | Brynjelsen Sean EVP, Business Development | Sagent Pharmaceuticals, Inc. (SGNT) | 29-Aug-16 | Disposition | 9,844 | $21.75 | $214,107.00 | (100%) 9.84K to 0 | (< 1%) |
| 31-Aug-16 6:11 PM View: | Yanai Shlomo Director | Sagent Pharmaceuticals, Inc. (SGNT) | 29-Aug-16 | Disposition | 742 | $21.75 | $16,138.50 | (100%) 0.74K to 0 | (< 1%) |
| 31-Aug-16 6:24 PM View: | Krizman Anthony Director | Sagent Pharmaceuticals, Inc. (SGNT) | 29-Aug-16 | Disposition (change in control) | 7,097 | $21.75 | $154,360.00 | (100%) 7.1K to 0 | (< 1%) |
| 31-Aug-16 6:25 PM View: | Jonathon M Singer EVP and CFO | Sagent Pharmaceuticals, Inc. (SGNT) | 29-Aug-16 | Disposition | 30,871 | $21.75 | $671,444.00 | (80%) 38.73K to 7.86K | (< 1%) |
| 01-Sep-16 6:03 PM View: | Vivo Ventures V, LLC 10% Owner | Sagent Pharmaceuticals, Inc. (SGNT) | 29-Aug-16 | Disposition (change in control) | 3,013,760 | $21.75 | $65,549,400.00 | (100%) 3.01M to 0 | |
| 31-Aug-16 6:23 PM View: | Behrens Mary Taylor Director | Sagent Pharmaceuticals, Inc. (SGNT) | 29-Aug-16 | Disposition (change in control) | 7,097 | $21.75 | $154,360.00 | (100%) 7.1K to 0 | (< 1%) |
| 31-Aug-16 6:25 PM View: | Jonathon M Singer EVP and CFO | Sagent Pharmaceuticals, Inc. (SGNT) | 29-Aug-16 | Disposition (change in control) | 7,857 | $21.75 | $170,890.00 | (100%) 7.86K to 0 | (< 1%) |
| 31-Aug-16 6:19 PM View: | Harmon J Frank EVP, Global Operations | Sagent Pharmaceuticals, Inc. (SGNT) | 29-Aug-16 | Disposition | 8,915 | $21.75 | $193,901.00 | (100%) 8.91K to 0 | (< 1%) |
| 31-Aug-16 6:21 PM View: | Ward Michael V. Chief Legal Off. and Secretary | Sagent Pharmaceuticals, Inc. (SGNT) | 29-Aug-16 | Disposition (change in control) | 1,000 | $21.75 | $21,750.00 | (62%) 1.6K to 0.6K | (< 1%) |
| 31-Aug-16 6:24 PM View: | Bullock Donald R Executive V.P. Sales | Sagent Pharmaceuticals, Inc. (SGNT) | 29-Aug-16 | Disposition | 8,073 | $21.75 | $175,588.00 | (76%) 10.66K to 2.58K | (< 1%) |
| 31-Aug-16 6:23 PM View: | Flanagan Robert J Director | Sagent Pharmaceuticals, Inc. (SGNT) | 29-Aug-16 | Disposition (change in control) | 435,770 | $21.75 | $9,478,000.00 | (100%) 435.77K to 0 | (< 1%) |
| 31-Aug-16 6:25 PM View: | Oberman Allan Chief Executive Officer Director | Sagent Pharmaceuticals, Inc. (SGNT) | 29-Aug-16 | Disposition | 101,986 | $21.75 | $2,218,200.00 | (100%) 101.99K to 0 | (< 1%) |
| 31-Aug-16 6:21 PM View: | Fekete Michael Director | Sagent Pharmaceuticals, Inc. (SGNT) | 29-Aug-16 | Disposition | 2,283 | $21.75 | $49,655.20 | (53%) 4.32K to 2.04K | (< 1%) |
| 31-Aug-16 6:23 PM View: | Flanagan Robert J Director | Sagent Pharmaceuticals, Inc. (SGNT) | 16-Aug-16 | Gift | 4,150 | -- | -- | (< 1%) 447.97K to 443.82K | |
| 05-Aug-16 5:17 PM View: | Oberman Allan Chief Executive Officer Director | Sagent Pharmaceuticals, Inc. (SGNT) | 03-Aug-16 | Payment of Exercise | 4,271 | $21.74 | $92,851.50 | (4%) 106.26K to 101.99K | < 1% |
| 13-Jul-16 2:28 PM View: | Fekete Michael Director | Sagent Pharmaceuticals, Inc. (SGNT) | 10-Jul-16 | Option Exercise | 591 | -- | -- | 12% 5.06K to 5.65K | |
| 28-Jun-16 4:02 PM View: | Bullock Donald R Executive V.P. Sales | Sagent Pharmaceuticals, Inc. (SGNT) | 27-Jun-16 | Grant | 4,993 | -- | -- | 88% 5.66K to 10.66K | |
| 25-Apr-16 4:37 PM View: | Vivo Ventures Vi, LLC 10% Owner | Sagent Pharmaceuticals, Inc. (SGNT) | 21-Apr-16 | Market Sale | 2,316 | $13.55 | $31,381.80 | (< 1%) 3.48M to 3.48M | 5% |
| 25-Apr-16 4:34 PM View: | Vivo Ventures V, LLC 10% Owner | Sagent Pharmaceuticals, Inc. (SGNT) | 21-Apr-16 | Market Sale | 2,005 | $13.55 | $27,167.80 | (< 1%) 3.02M to 3.01M | 5% |
| 01-Sep-16 6:01 PM View: | Vivo Ventures Vi, LLC 10% Owner | Sagent Pharmaceuticals, Inc. (SGNT) | 21-Apr-16 | Market Sale Duplicate | 2,316 | $13.55 | $31,381.80 | (< 1%) 3.48M to 3.48M | (60%) |
| 18-Apr-16 11:58 AM View: | Yanai Shlomo Director | Sagent Pharmaceuticals, Inc. (SGNT) | 15-Apr-16 | Option Exercise | 742 | -- | -- | 100% 0 to 0.74K | |
| 06-Apr-16 3:32 PM View: | Brynjelsen Sean EVP, Business Development | Sagent Pharmaceuticals, Inc. (SGNT) | 04-Apr-16 | Grant | 9,844 | -- | -- | 100% 0 to 9.84K | |
| 22-Mar-16 10:39 AM View: | Patterson Albert EVP, Nat. Accts and Corp. Dev. | Sagent Pharmaceuticals, Inc. (SGNT) | 19-Mar-16 | Payment of Exercise | 66 | $12.39 | $817.74 | (< 1%) 48.76K to 48.69K | (< 1%) |
| 16-Mar-16 2:08 PM View: | Harmon J Frank EVP, Global Operations | Sagent Pharmaceuticals, Inc. (SGNT) | 14-Mar-16 | Grant | 8,915 | -- | -- | 100% 0 to 8.91K | |
| 26-Feb-16 10:26 AM View: | Logerfo Michael President, CLO | Sagent Pharmaceuticals, Inc. (SGNT) | 25-Feb-16 | Payment of Exercise | 402 | $14.58 | $5,861.16 | (< 1%) 54.69K to 54.29K | 1% |
| 25-Feb-16 5:00 PM View: | Flanagan Robert J Director | Sagent Pharmaceuticals, Inc. (SGNT) | 25-Feb-16 | Option Exercise | 690 | -- | -- | < 1% 447.28K to 447.97K | |
| 25-Feb-16 5:00 PM View: | Krizman Anthony Director | Sagent Pharmaceuticals, Inc. (SGNT) | 25-Feb-16 | Option Exercise | 690 | -- | -- | 11% 6.41K to 7.1K | |
| 25-Feb-16 5:00 PM View: | Behrens Mary Taylor Director | Sagent Pharmaceuticals, Inc. (SGNT) | 25-Feb-16 | Option Exercise | 690 | -- | -- | 11% 6.41K to 7.1K | |
| 25-Feb-16 6:26 PM View: | Jonathon M Singer EVP and CFO | Sagent Pharmaceuticals, Inc. (SGNT) | 25-Feb-16 | Payment of Exercise | 334 | $14.58 | $4,869.72 | (< 1%) 39.06K to 38.73K | 1% |
| 25-Feb-16 5:00 PM View: | Fekete Michael Director | Sagent Pharmaceuticals, Inc. (SGNT) | 25-Feb-16 | Option Exercise | 690 | -- | -- | 16% 4.37K to 5.06K | |
| 25-Feb-16 5:00 PM View: | Patterson Albert EVP, Nat. Accts and Corp. Dev. | Sagent Pharmaceuticals, Inc. (SGNT) | 25-Feb-16 | Payment of Exercise | 373 | $14.58 | $5,438.34 | (< 1%) 49.13K to 48.76K | 1% |
| 25-Feb-16 5:00 PM View: | Drake Lorin Executive VP, Sales | Sagent Pharmaceuticals, Inc. (SGNT) | 25-Feb-16 | Payment of Exercise | 335 | $14.58 | $4,884.30 | (< 1%) 39.51K to 39.17K | 1% |
| 23-Feb-16 5:55 PM View: | Behrens Mary Taylor Director | Sagent Pharmaceuticals, Inc. (SGNT) | 22-Feb-16 | Option Exercise | 567 | -- | -- | 10% 5.84K to 6.41K | |
| 23-Feb-16 5:54 PM View: | Jonathon M Singer EVP and CFO | Sagent Pharmaceuticals, Inc. (SGNT) | 22-Feb-16 | Payment of Exercise | 468 | $14.61 | $6,837.48 | (1%) 39.53K to 39.06K | (1%) |
| 23-Feb-16 5:55 PM View: | Fekete Michael Director | Sagent Pharmaceuticals, Inc. (SGNT) | 22-Feb-16 | Option Exercise | 567 | -- | -- | 15% 3.8K to 4.37K | |
| 23-Feb-16 5:55 PM View: | Drake Lorin Executive VP, Sales | Sagent Pharmaceuticals, Inc. (SGNT) | 22-Feb-16 | Grant | 8,214 | -- | -- | 26% 31.63K to 39.84K | |
| 23-Feb-16 5:54 PM View: | Jonathon M Singer EVP and CFO | Sagent Pharmaceuticals, Inc. (SGNT) | 22-Feb-16 | Grant | 16,427 | -- | -- | 71% 23.1K to 39.53K | |
| 23-Feb-16 5:55 PM View: | Shea Thomas Joseph VP, Global Alliance Management | Sagent Pharmaceuticals, Inc. (SGNT) | 22-Feb-16 | Grant | 4,962 | -- | -- | 91% 5.48K to 10.44K | |
| 23-Feb-16 5:54 PM View: | Patterson Albert EVP, Nat. Accts and Corp. Dev. | Sagent Pharmaceuticals, Inc. (SGNT) | 22-Feb-16 | Payment of Exercise | 406 | $14.61 | $5,931.66 | (< 1%) 49.53K to 49.13K | (1%) |
| 23-Feb-16 5:55 PM View: | Drake Lorin Executive VP, Sales | Sagent Pharmaceuticals, Inc. (SGNT) | 22-Feb-16 | Payment of Exercise | 335 | $13.00 | $4,355.00 | (< 1%) 39.84K to 39.51K | |
| 23-Feb-16 5:55 PM View: | Oberman Allan Chief Executive Officer Director | Sagent Pharmaceuticals, Inc. (SGNT) | 22-Feb-16 | Grant | 51,335 | -- | -- | 93% 54.92K to 106.26K | |
| 23-Feb-16 5:54 PM View: | Logerfo Michael President, CLO | Sagent Pharmaceuticals, Inc. (SGNT) | 22-Feb-16 | Payment of Exercise | 486 | $14.61 | $7,100.46 | (< 1%) 55.18K to 54.69K | (1%) |
| 23-Feb-16 5:54 PM View: | Patterson Albert EVP, Nat. Accts and Corp. Dev. | Sagent Pharmaceuticals, Inc. (SGNT) | 22-Feb-16 | Grant | 8,214 | -- | -- | 20% 41.32K to 49.53K | |
| 23-Feb-16 5:54 PM View: | Flanagan Robert J Director | Sagent Pharmaceuticals, Inc. (SGNT) | 22-Feb-16 | Option Exercise | 567 | -- | -- | < 1% 446.71K to 447.28K |
